Lyvispah™ (baclofen) – New drug approval
November 22, 2021 - The FDA approved Saol Therapeutics’ Lyvispah (baclofen), for the treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Lyvispah may also be of some value in patients with spinal cord injuries and other spinal cord diseases.
Top